Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
Agenus announced that four abstracts highlighting botensilimab alone or with balstilimab have been accepted for presentation at the ASCO 2026 Annual Meeting. The lineup includes the first Phase 2 clinical data presentation for advanced cutaneous melanoma, alongside trials-in-progress for colorectal cancer and translational biomarker research.
Key figures
- Drug Name
- Botensilimab (with or without Balstilimab)
- Phase Of Trial
- Phase 2
- Patients treated bot bal
- 1200
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.